高级检索
当前位置: 首页 > 详情页

Biological evaluation and molecular docking of baicalin and scutellarin as Helicobacter pylori urease inhibitors

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]College of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, P.R. China [2]Guangzhou Wanglaoji Pharmaceutical Company Limited, Guangzhou, Guangdong 510450, P.R. China [3]The First Affiliated Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510405, P.R. China d Guangdong Institute of Microbiology, Guangzhou 510006, P.R. China [4]Dongguan Mathematical Engineering Academy of Chinese Medicine, Guangzhou, University of Chinese Medicine, Dongguan 523000, P.R. China [5]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510120, P.R. China
出处:
ISSN:

关键词: Baicalin Scutellarin Helicobacter pylori Urease Non-competitive inhibitior Molecular docking

摘要:
Ethnopharmacological relevance: Baicalin and scutellarin are the principal bioactive components of Scutellaria baicalensis Georgi which has extensively been incorporated into heat-clearing and detoxification formulas for the treatment of Helicobacter pylori-related gastrointestinal disorders in traditional Chinese medicine. However, the mechanism of action remained to be defined. Aim of the study: To explore the inhibitory effect, kinetics and mechanism of Helicobacter pylori urease (the vital pathogenetic factor for Helicobacter pylori infection) inhibition by baicalin and scutellarin, for their therapeutic potential. Materials and methods: The ammonia formations, indicator of urease activity, were examined using modified spectrophotometric Berthelot (phenol-hypochlorite) method. The inhibitory effect of baicalin and scutellarin was characterized with IC50 values, compared to acetohydroxamic acid (AHA), a well known Helicobacter pylori urease inhibitor. Lineweaver-Burk and Dixon plots for the Helicobacter pylori urease inhibition of baicalin and scutellarin was constructed from the kinetic data. SH-blocking reagents and competitive active site Ni2+ binding inhibitors were employed for mechanism study. Molecular docking technique was used to provide some information on binding conformations as well as confirm the inhibition mode. Moreover, cytotoxicity experiment using Gastric Epithelial Cells (GES-1) was evaluated. Results: Baicalin and scutellarin effectively suppressed Helicobacter pylori urease in dose-dependent and time-independent manner with IC50 of 0.82 +/- 0.07 mM and 0.47 +/- 0.04 mM, respectively, compared to AHA (IC50 = 0.14 +/- 0.05 mM). Structure-activity relationship disclosed 4'-hydroxyl gave flavones an advantage to binding with Helicobacter pylori urease. Kinetic analysis revealed that the types of inhibition were noncompetitive and reversible with inhibition constant K-i of 0.14 +/- 0.01 mM and 0.18 +/- 0.02 mM for baicalin and scutellarin, respectively. The mechanism of urease inhibition was considered to be blockage of the SH groups of Helicobacter pylori urease, since thiol reagents (L,D-dithiothreitol, L-cysteine and glutathione) abolished the inhibitory action and competitive active site Ni2+ binding inhibitors (boric acid and sodium fluoride) carried invalid effect Molecular docking study further supported the structure-activity analysis and indicated that baicalin and scutellarin interacted with the key residues Cys321 located on the mobile flap through S-H . pi interaction, but did not interact with active site Ni2+. Moreover, Baicalin (at 0.59-1.05 mM concentrations) and scutellarin (at 023-0.71 mM concentrations) did not exhibit significant cytotoxicity to GES-1. Conclusions: Baicalin and scutellarin were non-competitive inhibitors targeting sulfhydryl groups especially Cys321 around the active site of Helicobacter pylori urease, representing potential to be good candidate for future research as urease inhibitor for treatment of Helicobacter pylori infection. Furthermore, our work gave additional scientific support to the use of Scutellarki baicalensis in traditional Chinese medicine (TCM) to treat gastrointestinal disorders. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 医学
小类 | 2 区 全科医学与补充医学 3 区 药物化学 3 区 药学 3 区 植物科学
最新[2025]版:
大类 | 2 区 医学
小类 | 1 区 全科医学与补充医学 1 区 药学 2 区 药物化学 2 区 植物科学
JCR分区:
出版当年[2013]版:
Q1 PLANT SCIENCES Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q2 PHARMACOLOGY & PHARMACY Q2 CHEMISTRY, MEDICINAL
最新[2023]版:
Q1 CHEMISTRY, MEDICINAL Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 PHARMACOLOGY & PHARMACY Q1 PLANT SCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]College of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, P.R. China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号